EDINBURGH, Scotland, Sept. 24,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that Chief Executive Officer Bryan
Kobel has been invited to present at the ThinkEquity
Conference on October 30, 2024, at
the Mandarin Oriental Hotel in New York
City.
Mr. Kobel plans to provide insight into the company's clinical
trials as well as recent improvements to TC BioPharm's balance
sheet. For more information or to schedule a meeting
with management, please contact; IR@tcbiopharm.com.
The ThinkEquity Conference is a premier showcase of private and
public emerging growth companies from all over the world, this
conference features presentations by public and private
companies across many sectors.
About ThinkEquity
ThinkEquity is a boutique investment bank created by experienced
professionals who have worked together for over a decade,
collectively financing over $50
billion of public and private capital raises,
restructurings, and mergers and acquisitions. The ThinkEquity model
is built around the client's needs, no matter how complicated or
around-the-clock attention required, and to identify solutions that
help them create value for their investors.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
gamma-delta T-cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute
myeloid leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-to-present-at-the-2024-thinkequity-conference-in-nyc-302257052.html
SOURCE TC BioPharm
